Tolvaptan is an FDA-approved V2R antagonist for the treatment of PKD, which reduces intracellular cAMP levels in the kidney’s collecting duct and has been demonstrated to successfully slow down the progression of ADPKD. Here, AVPR2 is linked to autosomal dominant polycystic kidney disease.